Latest News and Press Releases
Want to stay updated on the latest news?
-
Dr. Jackson Ewing emphasizes the need for a robust policy framework to incentivize green hydrogen production and adoption SANTA CLARITA, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NewHydrogen,...
-
COLUMBUS, Ohio, June 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
-
Long Beach, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Duke University Men’s Soccer Head Coach John Kerr and student-athletes currently on the Duke University Men’s Soccer team have partnered with...
-
WALNUT CREEK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Vivacitas Oncology, Inc., a privately-held biopharmaceutical company focused on tough-to-treat cancers, continues to grow its Neuro-Oncology...
-
Cryo-Cell International (symbol: CCEL) Purchases Real Estate Location for its Institute for Cellular Therapies in the Raleigh-Durham area. MIAMI, Aug. 20, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell...
-
MIAMI, May 10, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell’s Medical Director, Dr. Joanne Kurtzberg and her research team at The Marcus Center for Cellular Cures (MC3) at Duke University School of Medicine...
-
MIAMI, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (symbol: CCEL), the world’s first private cord blood bank to separate and store stem cells, has entered into a collaborative...
-
OLDSMAR, Fla., June 11, 2020 (GLOBE NEWSWIRE) -- Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the “Company”), the world’s first private cord blood bank to separate and store...
-
KANSAS CITY, Mo., Aug. 23, 2018 (GLOBE NEWSWIRE) -- Cerner, a global leader in health care technology, collaborated with Duke Clinical Research Institute to develop an atherosclerotic cardiovascular...
-
IMPROVED SURVIVAL IN CHILDREN WITH GRAFT VERSUS HOST DISEASE WHO RESPOND TO MESOBLAST'S CELL THERAPY
NEW YORK CITY and MELBOURNE, Australia, Feb. 15, 2015 (GLOBE NEWSWIRE) -- Results of 160 pediatric patients treated with Mesoblast's proprietary allogeneic Tier 1 product candidate MSC-100-IV for...